Abstract
Aclidinium is a new anticholinergic agent for maintenance therapy of chronic obstructive pulmonary disease (COPD). Pharmacokinetic properties of aclidinium provide higher safety profile and lower risk of extrapulmonary adverse effects. In clinical phase III studies, aclidinium significantly increased lung function, reduced clinical symptoms and improved quality of life in patients with COPD. The aim of this review was to analyze clinical trials evaluating pharmacokinetics, clinical efficacy and safety of inhaled aclidinium bromide.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
